There seems to be a lot of myopic holders who think that just because the technology might work that nothing else matters.
If this sell off, which has seen 65% of company value lost, hasn't shown you that the market values more than just the technology then you're missing the lesson.
The market is very concerned that the IBX management team can't run a 15 person trial successfully. And if they can't run this one then how will they run a much larger trial. Bob has said that the money they raised last year was for a bigger trial, but it's also increasingly looking like that money will be used to keep the lights on while they scramble to try and get this trial to finish. Fortunately the options are still in the money so cash isn't an issue - for now.
Every delay and every misstep pushes back commercialisation and potential revenues. It opens the door for other imaging tech to overtake what IBX is about. It sullys the company name and puts collaboration agreements at risk or makes them less likely to be signed.
The spions are a small piece of the puzzle and completely useless with the wrong management team to execute.
That being said, all we have so far is a delay. I expect that's all that it is. But don't write off a scrapping and reframing a new trial as impossible. The third site, which I think will be in Sydney if previous announcements are followed through, will obviously allow more patients to be screened and increases the chances of an enrollment.
In two weeks there will be the AGM. As a digital meeting it will be very easy for Geoff and Bob to gag questions and stifle shareholders, let's just see whether they run and hide or face the music.
